A prospective examination of octreotide‐induced gall‐bladder changes in acromegaly

Richard C. Eastman, Richard F. Arakaki, Thomas Shawker, Roxanne Schock, Paris Roach, Richard J. Coml, Phillip Gorden

Research output: Contribution to journalArticle

16 Scopus citations

Abstract

objective We wished to determine the effects of octreetide acetate, a somatostatin analogue, on gall‐bladder function during treatment of acromegaly desiqn We used a prospective, open label trial of somatostatin analogue patients Seventeen patients with acromegaly took part measurements Ultrasonographic evaluation of gallbladder contents were performed pretreatment, after 1 month, and subsequently at intervals of 3–6 months results Non‐shadowing floating echogenic particles were observed in the gall‐bladder in 12 of 17 patients after (mean ± SEM) 24·5±0·46 months of treatment. During longterm treatment (mean 20·8±4·3, median 13, range 1–59 months), ultrasound evidence for cholelithiasis was observed In four patients after 20·4 months (range 4·2±43) months of octreotide therapy. No symptoms of biliary tract disease have been observed. Duration of acromegaly, average GH, average IGF‐I, gender, age at entry, dose of analogue, and concurrent use of non‐steroldal anti‐inflammatory drugs did not affect the occurrence of sludge or gallstones conclusions Formation of non‐shadowing, floating echogenic particles occurs commonly during the first 6 months of treatment with octreotide acetate. Cholelithiasis is a risk of long‐term treatment

Original languageEnglish (US)
Pages (from-to)265-269
Number of pages5
JournalClinical Endocrinology
Volume36
Issue number3
DOIs
StatePublished - Mar 1992

    Fingerprint

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this